An open-label, multi-center study to evaluate the efficacy and safety of nilotinib in adult patients with gastrointestinal stromal tumors resistant or intolerant to imatinib and or to 2nd line tyrosine kinas (TK) inhibitor.
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 18 Jan 2011 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 18 Jan 2011 Actual patient number is 9 according to ClinicalTrials.gov record.
- 18 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.